Searchable abstracts of presentations at key conferences in endocrinology

ea0077p48 | Metabolism, Obesity and Diabetes | SFEBES2021

The neuroophthalmological manifestations of obesity

Westgate Connar , Hagen Snorre , Israelsen Ida , Hamann Steffen , Jensen Rigmor , Eftekhari Sajedeh

Introduction: Obesity is associated with a plethora of metabolic and physiological side effects. Excess adiposity is associated with raised intracranial pressure (ICP) in obesity, where raised ICP sequalae include headache and visual decline in humans. We aimed to assess the effects of diet induced obesity (DIO) on ICP and related neuroophthalmological outcomes of headache behavior and retinal anatomy in rats.Methods: Female Sprague-Dawley rats received ...

ea0038fp4 | (1) | SFEBES2015

GLP-1 reduces cerebrospinal fluid secretion and intracranial pressure: a novel treatment for idiopathic intracranial hypertension?

Botfield Hannah , Uldall Maria , Mitchell James , Gonzalez Ana Maria , Jensen Rigmor , Sinclair Alexandra

Background: Idiopathic intracranial hypertension (IIH) predominantly affects obese women of childbearing age. IIH is characterised by increased intracranial pressure (ICP) which results in visual loss and disabling headaches. ICP dis-regulation results from imbalance of cerebrospinal fluid (CSF) production rate (at the choroid plexus epithelial cells) and drainage. Treatments for IIH are limited but weight loss is established as disease modifying.Glucago...

ea0050oc3.3 | Obesity, Diabetes Thyroid | SFEBES2017

The GLP-1R agonist exendin-4 reduces cerebrospinal fluid secretion and intracranial pressure

Botfield Hannah , Uldall Maria , Westgate Connar , Mitchell James , Hagen Snorre , Maria Gonzalez Ana , Hodson David , Jensen Rigmor , Sinclair Alexandra

Background: Current therapies for reducing raised intracranial pressure (ICP) in conditions such as idiopathic intracranial hypertension have limited efficacy and tolerability. As such, there is a pressing need to identify novel drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown to affect fluid homeostasis in the kidney. Here, we investigate whether exendin-4, a GLP-1R agonist, is able to modula...

ea0050oc3.3 | Obesity, Diabetes Thyroid | SFEBES2017

The GLP-1R agonist exendin-4 reduces cerebrospinal fluid secretion and intracranial pressure

Botfield Hannah , Uldall Maria , Westgate Connar , Mitchell James , Hagen Snorre , Maria Gonzalez Ana , Hodson David , Jensen Rigmor , Sinclair Alexandra

Background: Current therapies for reducing raised intracranial pressure (ICP) in conditions such as idiopathic intracranial hypertension have limited efficacy and tolerability. As such, there is a pressing need to identify novel drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown to affect fluid homeostasis in the kidney. Here, we investigate whether exendin-4, a GLP-1R agonist, is able to modula...